Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Editas Medicine Analyst Ratings and Price Targets | NASDAQ:EDIT | Benzinga
Editas Medicine Inc has a consensus price target of $9.44 based on the ratings of 21 analysts. The high is $17 issued by Raymond James on June 13, 2023. The low is $3 issued by Barclays on December 13, 2024. The 3 most-recent analyst ratings were released by Evercore ISI Group, RBC Capital, and Barclays on December 16, 2024, December 13, 2024, and December 13, 2024, respectively. With an average price target of $4 between Evercore ISI Group, RBC Capital, and Barclays, there's an implied 321.05% upside for Editas Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
RBC Capital
Barclays
Baird
Stifel
1calculated from analyst ratings
Analyst Ratings for Editas Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/16/2024 | Buy Now | 426.32% | Evercore ISI Group | Liisa Bayko69% | $7 → $5 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | JP Morgan | Brian Cheng38% | — | Downgrade | Neutral → Underweight | Get Alert |
| 12/13/2024 | Buy Now | 321.05% | RBC Capital | Luca Issi38% | $5 → $4 | Maintains | Sector Perform | Get Alert |
| 12/13/2024 | Buy Now | 215.79% | Barclays | Gena Wang50% | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/13/2024 | Buy Now | — | Chardan Capital | Geulah Livshits44% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 742.11% | Baird | Joel Beatty67% | $10 → $8 | Maintains | Outperform | Get Alert |
| 12/13/2024 | Buy Now | 215.79% | Stifel | Dae Gon Ha48% | $11 → $3 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2024 | Buy Now | 321.05% | Wells Fargo | Yanan Zhu35% | $7 → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/05/2024 | Buy Now | 1163.16% | Chardan Capital | Geulah Livshits44% | $12 → $12 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 426.32% | RBC Capital | Luca Issi38% | $8 → $5 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 1057.89% | Stifel | Dae Gon Ha48% | $17 → $11 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 742.11% | Truist Securities | Joon Lee77% | $12 → $8 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 636.84% | Wells Fargo | Yanan Zhu35% | $9 → $7 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | 426.32% | Barclays | Gena Wang50% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 10/23/2024 | Buy Now | 215.79% | Evercore ISI Group | Liisa Bayko69% | $7 → $3 | Maintains | In-Line | Get Alert |
| 10/23/2024 | Buy Now | 847.37% | Wells Fargo | Yanan Zhu35% | $27 → $9 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 1163.16% | Chardan Capital | Geulah Livshits44% | $20 → $12 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 742.11% | RBC Capital | Luca Issi38% | $8 → $8 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 1268.42% | Jones Trading | Soumit Roy33% | → $13 | Initiates | → Buy | Get Alert |
| 08/08/2024 | Buy Now | 636.84% | Barclays | Gena Wang50% | $9 → $7 | Maintains | Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 1163.16% | Truist Securities | Joon Lee77% | $20 → $12 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 1478.95% | B of A Securities | Greg Harrison42% | $13 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 06/18/2024 | Buy Now | 1163.16% | Oppenheimer | Jay Olson60% | $12 → $12 | Maintains | Perform | Get Alert |
| 05/30/2024 | Buy Now | 636.84% | Evercore ISI Group | Liisa Bayko69% | $15 → $7 | Maintains | In-Line | Get Alert |
| 05/09/2024 | Buy Now | 1478.95% | Citigroup | Samantha Semenkow33% | $16 → $15 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 636.84% | Morgan Stanley | Matthew Harrison61% | → $7 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 847.37% | Barclays | Gena Wang50% | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 02/29/2024 | Buy Now | 1584.21% | Citigroup | Samantha Semenkow33% | $11 → $16 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 1057.89% | Barclays | Gena Wang50% | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 847.37% | JP Morgan | Brian Cheng38% | $8 → $9 | Maintains | Neutral | Get Alert |
| 12/12/2023 | Buy Now | 2005.26% | Truist Securities | Joon Lee77% | $15 → $20 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 1057.89% | Citigroup | Samantha Semenkow33% | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 10/18/2023 | Buy Now | 742.11% | JP Morgan | Brian Cheng38% | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt28% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/29/2023 | Buy Now | 1689.47% | Stifel | Dae Gon Ha48% | $9 → $17 | Upgrade | Hold → Buy | Get Alert |
| 09/13/2023 | Buy Now | 1373.68% | Cantor Fitzgerald | Rick Bienkowski26% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 1373.68% | Cantor Fitzgerald | Rick Bienkowski26% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 1163.16% | Oppenheimer | Jay Olson60% | → $12 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | Buy Now | 1900% | Chardan Capital | Geulah Livshits44% | $22 → $19 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 1478.95% | Cantor Fitzgerald | Rick Bienkowski26% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | Buy Now | 1689.47% | Raymond James | Steven Seedhouse58% | → $17 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 1163.16% | Oppenheimer | Jay Olson60% | → $12 | Reiterates | → Perform | Get Alert |
| 05/08/2023 | Buy Now | 742.11% | RBC Capital | Luca Issi38% | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 05/08/2023 | Buy Now | 1373.68% | Credit Suisse | Richard Law43% | $15 → $14 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 2215.79% | Chardan Capital | Geulah Livshits44% | → $22 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 1478.95% | Credit Suisse | Richard Law43% | $13 → $15 | Maintains | Neutral | Get Alert |
| 02/23/2023 | Buy Now | 2215.79% | Chardan Capital | Geulah Livshits44% | $35 → $22 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 952.63% | RBC Capital | Luca Issi38% | $14 → $10 | Maintains | Sector Perform | Get Alert |
| 02/01/2023 | Buy Now | 1478.95% | Cantor Fitzgerald | Rick Bienkowski26% | → $15 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 636.84% | Morgan Stanley | Matthew Harrison61% | $8 → $7 | Maintains | Underweight | Get Alert |
| 01/23/2023 | Buy Now | 636.84% | SVB Leerink | Mani Foroohar47% | $6 → $7 | Maintains | Market Perform | Get Alert |
| 01/10/2023 | Buy Now | 531.58% | SVB Leerink | Mani Foroohar47% | $7 → $6 | Maintains | Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 3689.47% | Wells Fargo | Yanan Zhu35% | $50 → $36 | Maintains | Overweight | Get Alert |
| 12/13/2022 | Buy Now | 1057.89% | Citigroup | Samantha Semenkow33% | → $11 | Initiates | → Neutral | Get Alert |
| 12/06/2022 | Buy Now | 1268.42% | Credit Suisse | Richard Law43% | → $13 | Assumes | → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 1478.95% | B of A Securities | Greg Harrison42% | $18 → $15 | Maintains | Neutral | Get Alert |
| 11/18/2022 | Buy Now | 3584.21% | Truist Securities | Joon Lee77% | $80 → $35 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 1794.74% | Baird | Joel Beatty67% | $25 → $18 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | 742.11% | Morgan Stanley | Matthew Harrison61% | $10 → $8 | Maintains | Underweight | Get Alert |
| 11/18/2022 | Buy Now | 1373.68% | RBC Capital | Luca Issi38% | $32 → $14 | Maintains | Sector Perform | Get Alert |
| 11/18/2022 | Buy Now | 1163.16% | Oppenheimer | Jay Olson60% | $28 → $12 | Downgrade | Outperform → Perform | Get Alert |
| 11/18/2022 | Buy Now | 1268.42% | Credit Suisse | Tiago Fauth41% | $25 → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 3584.21% | Chardan Capital | Geulah Livshits44% | $43 → $35 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 636.84% | SVB Leerink | Mani Foroohar47% | $14 → $7 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 952.63% | Morgan Stanley | Matthew Harrison61% | $15 → $10 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | 3268.42% | RBC Capital | Luca Issi38% | $40 → $32 | Maintains | Sector Perform | Get Alert |
| 11/03/2022 | Buy Now | 2531.58% | Baird | Joel Beatty67% | $30 → $25 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 4426.32% | Chardan Capital | Geulah Livshits44% | $60 → $43 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 1163.16% | SVB Leerink | Mani Foroohar47% | $14 → $12 | Maintains | Market Perform | Get Alert |
| 09/29/2022 | Buy Now | 1794.74% | B of A Securities | Greg Harrison42% | → $18 | Initiates | → Neutral | Get Alert |
| 08/04/2022 | Buy Now | 1689.47% | Barclays | Gena Wang50% | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 05/24/2022 | Buy Now | 742.11% | Goldman Sachs | Madhu Kumar73% | $10 → $8 | Maintains | Sell | Get Alert |
| 05/09/2022 | Buy Now | 1478.95% | Morgan Stanley | Matthew Harrison61% | $17 → $15 | Maintains | Underweight | Get Alert |
| 04/12/2022 | Buy Now | 1689.47% | Morgan Stanley | Matthew Harrison61% | $16 → $17 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Editas Medicine (EDIT) stock?
The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by Evercore ISI Group on December 16, 2024. The analyst firm set a price target for $5.00 expecting EDIT to rise to within 12 months (a possible 426.32% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ:EDIT) was provided by Evercore ISI Group, and Editas Medicine maintained their outperform rating.
When was the last upgrade for Editas Medicine (EDIT)?
The last upgrade for Editas Medicine Inc happened on August 8, 2024 when B of A Securities raised their price target to $15. B of A Securities previously had a neutral for Editas Medicine Inc.
When was the last downgrade for Editas Medicine (EDIT)?
The last downgrade for Editas Medicine Inc happened on December 16, 2024 when JP Morgan changed their price target from N/A to N/A for Editas Medicine Inc.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a maintained with a price target of $7.00 to $5.00. The current price Editas Medicine (EDIT) is trading at is $0.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.